Abstract
The Department of Health and Social Care (DHSC) has said it is working on guidance to help prescribers navigate shortages of glucagon-like peptide-1 (GLP-1) receptor agonists. On 30 September 2022, the Pharmaceutical Services Negotiating Service (PSNC) issued medicine supply notifications for the type 2 diabetes mellitus (T2DM) medicines semaglutide (Ozempic; Novo Nordisk) — which was approved in September […]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
